Core Viewpoint - Ekso Bionics (EKSO) has experienced a downtrend, losing 10.1% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, suggesting that despite a downtrend, buyers are starting to emerge [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength depends on its placement on the chart [6]. Fundamental Analysis - There has been a significant upward trend in earnings estimate revisions for EKSO, which is a bullish indicator, as these revisions are strongly correlated with near-term stock price movements [7]. - The consensus EPS estimate for the current year has increased by 77% over the last 30 days, indicating strong agreement among analysts regarding EKSO's potential for better earnings [8]. - EKSO holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Ekso Bionics (EKSO) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.2. This compares to a loss of $1.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.33%. A quarter ago, it was expected that this robotic exoskeleton company would post a loss of $1.65 per share when it actually produced a loss of $1.8, delivering a surprise of -9.09%.Over the last four quarters, the com ...

Financial Data and Key Metrics Changes - The company recorded revenue of $2.1 million for Q2 2025, down from $5 million in Q2 2024, primarily due to short-term delays in multi-device enterprise health sales, partially offset by higher sales of the Ekso Indigo personal device [8] - Gross profit for Q2 2025 was $800,000, representing a gross margin of approximately 40%, compared to a gross profit of $2.6 million and a gross margin of 53% for the same period in 2024 [8] - Operating expenses for Q2 2025 were $4.8 million, a 4% improvement from $5 million in Q2 2024 [9] - The net loss applicable to common stockholders for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, for the same period in 2024 [9] Business Line Data and Key Metrics Changes - The legacy enterprise health product, primarily the EksoNR device, faced revenue declines, while the Ekso Indigo personal device saw increased sales, contributing to a 50% growth in personal health product revenues in the first half of 2025 [13][21] - Despite total revenues for the first six months of 2025 being down 38% compared to the same period in 2024, personal health product revenues grew by more than 50% [13] Market Data and Key Metrics Changes - The company is experiencing a trend of lower but steady growth in the legacy enterprise health business, counterweighted by growth in personal health from the Ekso Indigo device [13] - The company has developed a pipeline of over 45 Medicare beneficiaries qualified for the Ekso Indigo personal device, up more than 200% from the end of 2024 [16] Company Strategy and Development Direction - The company is focusing on a scalable go-to-market strategy for the Ekso Indigo personal device, supported by new distribution partners and educational initiatives like Ekso University [12][21] - A strategic initiative is underway to build a proprietary foundation model for human motion in physical rehabilitation, integrating new AI capabilities across the product portfolio [17][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the revenue shortfall in Q2 2025 does not reflect the overall health of the business and anticipates closing a significant portion of deferred sales in the second half of the year [11][20] - The company is actively working with partners to navigate market access and reimbursement processes, which are critical for the commercialization of personal devices [35] Other Important Information - The company joined the NVIDIA Connect program to enhance product development and cost efficiency, aiming to leverage AI in exoskeleton technology [17][19] - The company is working with Pria Healthcare to improve market access and reimbursement processes for the Ekso Indigo personal device [15][36] Q&A Session Summary Question: Can you quantify the deferred sales on the Enterprise Health side? - Management indicated that two multi-unit device sales fell out of Q2, with one being an international order delayed due to regulatory challenges and the other a North American order expected to occur in Q3, totaling approximately $1.4 million [24] Question: When do you expect the Indigo Personal to overtake the Enterprise Health business? - Management believes that by 2025, the contribution from personal health products will increase to about 25% of total revenue, with expectations to overtake enterprise health by 2027 [26] Question: How is the process of nailing down the patient profile progressing? - Management reported positive outcomes from appeals processes, with claims being approved when presented to administrative law judges, indicating that the technology is deemed medically necessary [29] Question: Will Ekso University focus solely on exoskeletons? - Management stated that while the initial courses focus on exoskeleton technology, future content will cover a wide range of neuro rehabilitation topics [30] Question: How many enterprise clients utilize federal grants? - Management estimated that approximately 10% of enterprise customers rely on federal or outside grants to fund their technology [41]

Financial Data and Key Metrics Changes - The company recorded revenue of $2.1 million for Q2 2025, down from $5 million in Q2 2024, primarily due to short-term delays in completing certain multi-device enterprise health sales [8][9] - Gross profit for Q2 2025 was $800,000, representing a gross margin of approximately 40%, compared to a gross profit of $2.6 million and a gross margin of 53% for the same period in 2024 [9] - Operating expenses for Q2 2025 were $4.8 million, a 4% improvement from $5 million in Q2 2024 [10] - The net loss applicable to common stockholders for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, for the same period in 2024 [10] Business Line Data and Key Metrics Changes - The legacy enterprise health product, primarily the EksoNR device, experienced a decrease in revenue, while sales of the Ekso Indigo personal device increased [9][12] - Personal health product revenues grew by more than 50% in the first half of 2025, despite total revenues being down 38% compared to the same period in 2024 [15][23] Market Data and Key Metrics Changes - The company noted that a small percentage of U.S. customers were impacted by the loss of federal grants and economic uncertainties, which may delay purchases into later 2025 or early 2026 [12][13] - The company has developed a pipeline of over 45 Medicare beneficiaries qualified for the Ekso Indigo Personal, up more than 200% from the end of 2024 [19] Company Strategy and Development Direction - The company is focusing on a scalable go-to-market strategy for the Ekso Indigo Personal, supported by new distribution partners and marketing efforts [23] - A strategic initiative is underway to build a proprietary foundation model for human motion in physical rehabilitation, integrating new AI capabilities across the product portfolio [20][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the second quarter revenue shortfall does not reflect the health of the current business or future prospects, citing expected closure of deferred sales [12][13] - The company is working to manage enterprise customer budgets and has engaged a third-party financial partner to assist in transitioning purchases from capital to operational budgets [42] Other Important Information - The company launched Ekso University, a virtual platform providing continuing education courses to physical therapists, aimed at increasing awareness and adoption of exoskeleton technology [14] - The company joined the NVIDIA Connect program to leverage AI and high-performance computing for product development [20][21] Q&A Session Summary Question: Can you quantify the deferred sales on the Enterprise Health side? - Management indicated that two multi-unit device sales fell out of Q2, with one being an international order and the other a North American IDN order expected to occur in Q3, totaling approximately $1.4 million [25][26] Question: When do you expect the Indigo Personal to overtake the Enterprise Health business? - Management believes that by 2025, the contribution from Personal Health will increase to about 25% of total revenue, with expectations to overtake Enterprise Health by 2027 [27][28] Question: How is the process of nailing down the patient profile progressing? - Management noted positive outcomes from recent ALJ hearings and emphasized the importance of ensuring the best claims possible for reimbursement [30] Question: Will Ekso University focus solely on exoskeletons? - Management stated that while initial courses will center on exoskeleton technology, future content will cover a broader range of neuro rehabilitation topics [32] Question: How are new collaborations aiding the commercialization of personal devices? - Management highlighted ongoing partnerships with industry leaders to navigate market access and build a scalable process for patient claims [37][40]

Investor Presentation July 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and expectations of management wit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 ...

Exhibit 99.1 SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments "While there was abnormal weakness in the second quarter, in large part due to what we believe are short-term delays in completing some multi-device Enterprise Health sa ...

Core Viewpoint - Ekso Bionics Holdings, Inc. reported a significant decline in revenue for the second quarter of 2025, primarily due to lower sales of Enterprise Health devices, but anticipates recovery in the second half of the year driven by growth in Personal Health products [3][4]. Financial Performance - For Q2 2025, the company recorded revenue of $2.1 million, down from $5.0 million in Q2 2024, attributed mainly to decreased Enterprise Health device sales [4]. - Gross profit for Q2 2025 was $0.8 million, with a gross margin of approximately 40%, compared to $2.6 million and a gross margin of 53% in Q2 2024 [5]. - The net loss for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, in Q2 2024 [7][17]. Expenses - Sales and marketing expenses for Q2 2025 were $1.7 million, slightly down from $1.8 million in Q2 2024, mainly due to lower discretionary payroll [6]. - Research and development expenses decreased to $0.9 million in Q2 2025 from $1.1 million in Q2 2024, primarily due to a reduction in headcount [6]. - General and administrative expenses increased to $2.3 million in Q2 2025 from $2.0 million in Q2 2024, attributed to lower allocable costs to manufacturing [7]. Cash Position - As of June 30, 2025, the company had cash and restricted cash totaling $5.2 million, down from $6.5 million at the end of 2024 [8][15]. Strategic Developments - The company named Bionic Prosthetics & Orthotics Group as its first distributor for the Ekso Indego Personal device within the orthotics and prosthetics industry [10]. - Ekso Bionics was accepted into the NVIDIA Connect program, aiming to develop a proprietary foundation model for human motion and integrate AI capabilities across its product portfolio [10]. - The launch of eksoUniversity provides a library of continuing education courses for physical therapists and assistants working with patients with neurological conditions [10].

Core Viewpoint - Ekso Bionics Holdings, Inc. is set to release its financial and business results for Q2 2025 on July 28, 2025, with a conference call scheduled to discuss these results and recent developments [1]. Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [3]. - The company focuses on improving health and quality of life through advanced robotics that enhance, amplify, and restore human function [3]. - Ekso Bionics is unique in offering technologies that assist individuals with paralysis to stand and walk, as well as enhancing capabilities in various job sites globally [3]. - The company is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq Capital Market under the symbol "EKSO" [3].

On-demand courses already approved for CEUs in over 30 statesSAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, is pleased to announce the launch of eksoUniversity, a new platform providing continuing education courses to physical therapists (“PTs”) and physical therapy assistants (“PTAs”) across the country. Most states require healthcare professional ...